Nutromics Raises $7.5M for Real-Time Wearable Diagnostics

Nutromics, a company developing innovative diagnostic technologies, has secured $7,500,000 in a recent funding round. The investment will support the advancement of its flagship product, the Lab-on-a-Patch®, which is described as the world’s first continuous, multiplex molecular monitoring platform. Nutromics's technology centers on a single wearable device that delivers real-time insights. Its modular microneedle patch incorporates advanced, AI-designed DNA-based biosensors, known as aptamers, to track multiple critical biomarkers concurrently. This adaptable platform can monitor a diverse array of analytes, from therapeutic drugs such as vancomycin to key indicators for sepsis and cardiac health, by simply modifying the DNA sequence. The company aims to bridge the current gap in diagnostics caused by delays in lab results, providing immediate molecular data to clinicians for proactive intervention and improved patient care. The $7,500,000 in secured capital represents a significant milestone for Nutromics, underscoring investor confidence in its approach to transforming medical diagnostics. The capital infusion is earmarked to accelerate the company's strategic growth initiatives. Nutromics plans to deploy the funds to further its research and development programs, scale its engineering and manufacturing capabilities, and prepare for future market entry of its innovative diagnostic solution. This funding round is expected to enable Nutromics to advance its core technology and expand its operational footprint. The company is focused on its goal of redefining diagnostics to meet modern healthcare demands, aspiring to offer a new standard for continuous molecular monitoring that can prevent complications, reduce costs, and ultimately save lives.